Abstract:Background: The aggregation and spread of misfolded amyloid structured proteins, such as tau and α-synuclein, are key pathological features associated with neurodegenerative disorders, including Alzheimer's and Parkinson's disease. These proteins possess a prion-like property, enabling their transmission from cell to cell leading to propagation throughout the central and peripheral nervous systems. While the mechanisms underlying their intracellular spread are still being elucidated, targeting the extracellular space has emerged as a potential therapeutic approach. The glymphatic system, a brain-wide pathway responsible for clearing extracellular metabolic waste from the central nervous system, has gained attention as a promising target for removing these toxic proteins. Methods: In this study, we investigated the impact of long-term modulation of glymphatic function on tau aggregation and spread by chronically treating a mouse model of tau propagation with a pharmacological inhibitor of AQP4, TGN-020. Thy1-hTau.P301S mice were intracerebrally inoculated with tau into the hippocampus and overlying cortex, and subsequently treated with TGN-020 (3 doses/week, 50 mg/kg TGN-020, i.p.) for 10-weeks. During this time, animal memory was studied using cognitive behavioural tasks, and structural MR images were acquired of the brain in vivo prior to brain extraction for immunohistochemical characterisation. Results: Our findings demonstrate increased tau aggregation in the brain and transhemispheric propagation in the hippocampus following the inhibition of glymphatic clearance. Moreover, disruption of the glymphatic system aggravated recognition memory in tau inoculated mice and exacerbated regional changes in brain volume detected in the model. When initiation of drug treatment was delayed for several weeks post-inoculation, the alterations were attenuated. Conclusions: These results indicate that by modulating AQP4 function and, consequently, glymphatic clearance, it is possible to modify the propagation and pathological impact of tau in the brain, particularly during the initial stages of the disease. These findings highlight the critical role of the glymphatic system in preserving healthy brain homeostasis and offer valuable insights into the therapeutic implications of targeting this system for managing neurodegenerative diseases characterized by protein aggregation and spread.

Activation of the heat shock response as a therapeutic strategy for tau toxicity

Exploiting the Diversity of the Heat-Shock Protein Family for Primary and Secondary Tauopathy Therapeutics

Shock and awe: unleashing the heat shock response to treat Huntington disease

A Tauopathy-Homing and Autophagy-Activating Nanoassembly for Specific Clearance of Pathogenic Tau in Alzheimer's Disease.

Heat Shock Protein 90 in Neurodegenerative Diseases

Small heat shock protein 22 kDa can modulate the aggregation and liquid-liquid phase separation behavior of tau

Stabilizing the Retromer Complex in a Human Stem Cell Model of Alzheimer’s Disease Reduces TAU Phosphorylation Independently of Amyloid Precursor Protein

Small molecules targeting molecular chaperones for tau regulation: Achievements and challenges

A Cns-Permeable Hsp90 Inhibitor Rescues Synaptic Dysfunction and Memory Loss in App-Overexpressing Alzheimer'S Mouse Model Via an Hsf1-Mediated Mechanism

Heat Shock Proteins Reduce Aggregation and Facilitate Degradation of Tau Protein

Roles of Heat-Shock Protein 90 in Maintaining and Facilitating the Neurodegenerative Phenotype in Tauopathies

Identification of novel small molecule chaperone activators for neurodegenerative disease treatment

Stimulatory effect of α-synuclein on the tau-phosphorylation by GSK-3β

5-HT4 receptor agonists treatment reduces tau pathology and behavioral deficit in the PS19 mouse model of tauopathy

Deletion of tau attenuates heat shock-induced injury in cultured cortical neurons

Phenotypic Discovery of Neuroprotective Agents by Regulation of Tau Proteostasis via Stress‐Responsive Activation of PERK Signaling

Hsp90 Maintains the Stability and Function of the Tau Phosphorylating Kinase GSK3β

Treatment with Tau fibrils impact Huntington's disease-related phenotypes in cell and mouse models

Glymphatic inhibition exacerbates tau propagation in an Alzheimer's disease model

All-Trans Retinoic Acid-Induced Cell Surface Heat Shock Protein 90 Mediates Tau Protein Internalization and Degradation in Human Microglia

Heat Shock Proteins in Alzheimer’s Disease: Role and Targeting